Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Preventiongenetics, |
RCV003407356 | SCV004109625 | pathogenic | MAP3K1-related condition | 2023-05-30 | criteria provided, single submitter | clinical testing | The MAP3K1 c.566T>C variant is predicted to result in the amino acid substitution p.Leu189Pro. This variant has been previously reported in an individual with 46,XY complete gonadal dysgenesis (Pearlman et al. 2010. PubMed ID: 21129722). Functional studies support its pathogenicity (Loke and Ostrer. 2012. PubMed ID: 22171599; Upadhyay et al. 2018. PubMed ID: 29095481; Chamberlin et al. 2019. PubMed ID: 30608580). Alternative nucleotide changes affecting the same amino acid (p.Leu189Arg and p.Leu189Gln) have also been reported in unrelated individuals with disorders of sex development (Pearlman et al. 2010. PubMed ID: 21129722; Granados et al. 2017. PubMed ID: 28504475). The c.566T>C (p.Leu189Pro) variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. In summary, this variant is interpreted as pathogenic. |
OMIM | RCV000023057 | SCV000044348 | pathogenic | 46,XY sex reversal 6 | 2010-12-10 | no assertion criteria provided | literature only |